Most-Read Cancer News of 2022
This year's most-read cancer news included researchers finding a possible liver cancer immunotherapy, cancer patients facing many negative impacts from COVID-19 and more.
- Researchers Identify Possible Liver Cancer Immunotherapy
A study in mice has found that a combination immunotherapy slowed tumor growth and activated anti-tumor immune response.
Read more - Patients With Cancer Faced Heightened Economic, Social, Psychological Impacts From COVID-19
A review of multiple studies found the COVID-19 exacerbated the economic, social and psychological difficulties that patients with cancer were already facing because of their cancer.
Read more - Study of a Tremelimumab-Imfinzi Combination May Lead to New Liver Cancer Treatment Strategy
Results of an AstraZeneca trial presented at a recent ASCO meeting sow hopes for a new treatment for patients diagnosed with unresectable hepatocellular carcinoma, the most common type of liver cancer.
Read more - Covid-19 Antibodies Found in Nonimmune Blood Cancer Patients After Receiving Booster
Patients with blood cancers have been reported to have less of a chance to develop immunity from the COVID-19 vaccination. However, new data has been found stating those who have been previously vaccinated with no immunity and then followed up with a booster dose, eventually developed antibodies against the virus.
Read more - Solving the Puzzle of Cancer and COVID-19 Vaccination
Recent treatment may affect the antibody response, particularly among those with hematologic cancers.
Read more
Verastem Begins Submission for Ovarian Cancer Combination
May 24th 2024Verastem is studying the combination of avutometinib and defactinib to treat low-grade serous ovarian cancer in patients with KRAS-mutations. The company plans to complete the new drug application in the second half of this year.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
